Apnimed Filed, US Offering, Nasdaq: APMD
Late-stage pharma developing oral therapies for sleep-related breathing diseases.
Industry: Health Care
Latest Trade: ()
First Day Return:
Return from IPO:
Industry: Health Care
Late-stage pharma developing oral therapies for sleep-related breathing diseases.
| IPO Data | |
|---|---|
| IPO File Date | 07/10/2026 |
| Offer Price | |
| Price Range n/a | |
| Offer Shares (mm) | n/a |
| Deal Size ($mm) | $100 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| IPO Data | |
|---|---|
| IPO Date | |
| Offer Price | |
| Price Range n/a | |
| Offer Shares (mm) | n/a |
| Deal Size ($mm) | $100 |
| Lock-Up Date | IPO Pro Only |
| Street Research | IPO Pro Only |
| Underwriters |
|---|
| BofA Securities |
| Evercore ISI |
more |
| Company Data | |
|---|---|
| Headquarters | Cambridge, MA, United States |
| Founded | 2017 |
| Employees at IPO | 65 |
| Website www.apnimed.com | |
IPO News for Apnimed
Apnimed (APMD) Performance
